Andrii Buvailo, PhD

Faro Health has partnered with Recursion to streamline clinical protocol design using Faro's AI-driven platform.

Eli Lilly announced the acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program for up to $2.5 billion, expanding its oncology pipeline with STX-478, a differentiated PI3Kα inhibitor currently in Phase 1/2 clinical trials.

Gilead Sciences has announced a $1.7 billion collaboration with LEO Pharma, expanding its portfolio beyond infectious diseases and into inflammatory conditions. The partnership focuses on developing oral STAT6 small-molecule inhibitors and targeted protein degraders. STAT6 is a transcription factor involved in IL-4 and IL-13 cytokine signaling, pathways implicated in diseases such as eczema, asthma, and COPD.

Atropos Health has announced a collaboration with Merck to utilize its suite of tools for real-world evidence (RWE) generation, including GENEVA OS, Green Button, and the Atropos Evidence Network. The partnership focuses on rapid cohort creation, advanced analytics, and generating publication-grade RWE within 48 hours.

Merck KGaA has integrated Quris-AI’s Bio-AI platform into its drug development pipeline to evaluate small molecule drug candidates for safety before clinical trials. The collaboration builds on a two-year validation study, where Quris-AI demonstrated higher accuracy in predicting drug-induced liver injury (DILI) compared to traditional preclinical methods, with the potential to reduce reliance on animal testing.

Calico, the Alphabet-backed biotech focused on aging and longevity, has encountered a hurdle in its efforts to develop treatments for amyotrophic lateral sclerosis (ALS). Massachusetts General Hospital’s Healy ALS Platform trial found that fosigotifator, a candidate developed in collaboration with AbbVie, failed to meet its primary endpoint, delivering no significant impact on slowing disease progression after 24 weeks of treatment.

(Last Update: December 2024, by adding Lab Spend, Labviva and more)

A life sciences marketplace is an online platform that operates with a "many-to-many" business logic, hosting multiple suppliers and buyers interacting via various e-commerce tools available as part of the website's functionality.

After securing $40 million in August 2024, Noetik—an AI-native biotechnology company—announced in a recently released technical report the launch of OCTO-VirtualCell, a next-generation AI model designed to reveal how cells behave in both healthy and disease contexts. Noetik leverages self-supervised machine learning and high-throughput spatial data to advance precision therapies.

Inflammatory Bowel Disease (IBD), a chronic and debilitating autoimmune disorder that includes ulcerative colitis and Crohn’s disease, impacts millions of lives globally. Characterized by chronic gut inflammation, intestinal barrier dysfunction, and increased risk of colitis-associated cancer, IBD remains an unmet clinical challenge. Current treatments, largely focused on anti-inflammatory drugs, offer symptomatic relief but fail to address epithelial barrier damage—a core issue in IBD progression. As a result, patients face the threat of disease recurrence, prolonged dependence on medications, and increased risk of colorectal cancer.